Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionLINCOLN VARIABLE INSURANCE PRODUCTS TRUST - LVIP Dimensional U.S. Core Equity 2 Fund Standard Class
Latest Disclosed Ownership2,500 shares
Latest Disclosed Value $ 61,900
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST - LVIP Dimensional U.S. Core Equity 2 Fund Standard Class ownership in CPRX / Catalyst Pharmaceuticals, Inc.

On May 18, 2026 - LINCOLN VARIABLE INSURANCE PRODUCTS TRUST - LVIP Dimensional U.S. Core Equity 2 Fund Standard Class filed a NPORT-P form disclosing ownership of 2,500 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $61,900 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 6, 2026 disclosing 2,500 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $78,725 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 62 5.17 0.0071
2026-02-06 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 58 18.37 0.0064
2025-11-21 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 49 -9.26 0.0053
2025-08-06 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 54 -10.00 0.0060
2025-05-19 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 61 15.38 0.0072
2025-02-06 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 52 6.12 0.0059
2024-11-18 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 50 28.95 0.0054
2024-08-08 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 39 -2.56 0.0043
2024-05-20 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 40 -7.14 0.0043
2024-02-07 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 42 44.83 0.0047
2023-11-20 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 29 -12.12 0.0036
2023-08-23 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 34 -19.51 0.0039
2023-05-23 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 41 -10.87 0.0051
2023-02-08 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 46 43.75 0.0060
2022-11-23 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 32 88.24 0.0045
2022-08-08 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 18 -15.00 0.0023
2022-05-26 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 21 25.00 0.0023
2022-02-08 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 17 23.08 0.0018
2021-11-23 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 13 -7.14 0.0015
2021-08-06 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 14 27.27 0.0016
2021-05-25 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 12 37.50 0.0013
2021-02-08 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 8 14.29 0.0010
2020-11-23 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 0 0.00 7 -36.36 0.0010
2020-08-06 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,500 2,500 12 0.0016
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.